BR9815170A - "método de obter composto aplicável no tratamento de asma em mamìferos" - Google Patents
"método de obter composto aplicável no tratamento de asma em mamìferos"Info
- Publication number
- BR9815170A BR9815170A BR9815170-3A BR9815170A BR9815170A BR 9815170 A BR9815170 A BR 9815170A BR 9815170 A BR9815170 A BR 9815170A BR 9815170 A BR9815170 A BR 9815170A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- straight
- optionally substituted
- alkylene groups
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 16
- 208000006673 asthma Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 abstract 15
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 230000009435 amidation Effects 0.000 abstract 1
- 238000007112 amidation reaction Methods 0.000 abstract 1
- 238000005576 amination reaction Methods 0.000 abstract 1
- 238000006477 desulfuration reaction Methods 0.000 abstract 1
- 230000023556 desulfurization Effects 0.000 abstract 1
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000026030 halogenation Effects 0.000 abstract 1
- 238000005658 halogenation reaction Methods 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Patente de invenção de "MéTODO DE OBTER COMPOSTO APLICáVEL NO TRATAMENTO DE ASMA EM MAMìFEROS". A invenção se refere mais especificamente compostos que sejam mais efetivos inibidores de PDE IV que aqueles da técnica anterior. O composto em questão apresenta a fórmula geral (I) : onde: Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH(CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= <MV>C ; e NH, N(C1-C3 alquila) , O,S,C(O)CH2 e OCH2; R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e R8 é uma alquila de cadeia reta ou ramificada ou uma cicloalquila C3-C8 opcionalmente substituída com OH. Segundo a invenção o composto é obtido pelas seguintes etapas: (a) reagir um composto da fórmula (II) : onde Z, R3 e R4 são como acima definido, com uma quantidade efetiva de um éster para formas um composto da fórmula (III) : onde Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH(CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= <MV>C ; e NH, N (C1-C3 alquila),O,S,C (O) CH2 e OCH2;R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e (b) submeter dito composto (III) a etapas sucessivas de aminação, redução e amidação para formar o composto(IV) ; onde: Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH (CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= <MV>C ; e NH, N(C1-C3 alquila),O,S,C (O) CH2 e OCH2; R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e R8 é uma alquila de cadeia reta ou ramificada ou uma cicloalquila C3-C8 opcionalmente substituída com OH. (.c) reagir dito composto (IV) com uma quantidade efetiva de uma base para formar o composto (V) Onde Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH(CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= <MV> C; e NH, N (C1-C3 alquila),O,S,C (O) CH2 e OCH2; R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e R8 é uma alquila de cadeia reta ou ramificada ou uma cicloalquila C3-C8 opcionalmente substituída com OH. (d) reagir dito composto(V) com uma quantidade efetiva de um composto de desulfuração para formar o composto (VI) : onde Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH(CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= MV>C ; e NH, N(C1-C3 alquila),O,S,C (O) CH2 e OCH2; R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e R8 é uma alquila de cadeia reta ou ramificada ou uma cicloalquila C3-C8 opcionalmente substituída com OH.; e (e) submeter dito composto(VI) a etapas sucessivas de halogenação e deslocamento para formar dito composto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937197P | 1997-12-12 | 1997-12-12 | |
| PCT/US1998/026340 WO1999031105A1 (en) | 1997-12-12 | 1998-12-10 | 3-substituted adenines via2-thioxanthines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9815170A true BR9815170A (pt) | 2000-10-10 |
Family
ID=22088545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815170-3A BR9815170A (pt) | 1997-12-12 | 1998-12-10 | "método de obter composto aplicável no tratamento de asma em mamìferos" |
| BR9815171-1A BR9815171A (pt) | 1997-12-12 | 1998-12-11 | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. |
| BR9815169-0A BR9815169A (pt) | 1997-12-12 | 1998-12-11 | "método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença." |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815171-1A BR9815171A (pt) | 1997-12-12 | 1998-12-11 | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. |
| BR9815169-0A BR9815169A (pt) | 1997-12-12 | 1998-12-11 | "método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença." |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US6037470A (pt) |
| EP (3) | EP1044201A4 (pt) |
| JP (5) | JP2002508377A (pt) |
| KR (3) | KR100349385B1 (pt) |
| CN (3) | CN1294590A (pt) |
| AT (1) | ATE244243T1 (pt) |
| AU (5) | AU1723099A (pt) |
| BR (3) | BR9815170A (pt) |
| CA (3) | CA2313004A1 (pt) |
| DE (3) | DE19882893T1 (pt) |
| DK (1) | DK1045849T3 (pt) |
| ES (1) | ES2202924T3 (pt) |
| GB (2) | GB2346878B (pt) |
| HU (3) | HUP0301166A2 (pt) |
| NO (1) | NO20002998L (pt) |
| PL (1) | PL341108A1 (pt) |
| PT (1) | PT1045849E (pt) |
| TR (1) | TR200001706T2 (pt) |
| WO (5) | WO1999031105A1 (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002541078A (ja) * | 1999-04-02 | 2002-12-03 | ユーロ−セルティーク，エス．エー． | ホスホジエステラーゼｉｖ阻害活性を有するプリン誘導体 |
| CA2379356A1 (en) * | 1999-08-12 | 2001-02-22 | Mark Chasin | Novel hypoxanthine and thiohypoxanthine compounds |
| BR0207302A (pt) * | 2001-02-08 | 2004-02-10 | Memory Pharm Corp | Trifluorometilpurinas como inibidores da fosfodiesterase 4 |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| CA2494026A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| US7332486B2 (en) * | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| US20040063938A1 (en) * | 2002-09-30 | 2004-04-01 | Pfizer Inc | Process for preparing haloalkyl pyrimidines |
| OA13187A (en) * | 2003-07-10 | 2006-12-13 | Achillion Pharmaceuticals Inc | Substituted arylthiourea derivatives useful as inhibitors of viral replication. |
| AR045134A1 (es) * | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
| US20080280926A1 (en) * | 2003-12-16 | 2008-11-13 | Palle Venkata P | Phosphodiesterase Inhibitors |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| DE102006033572A1 (de) | 2006-07-20 | 2008-01-24 | Bayer Cropscience Ag | N'-Cyano-N-halogenalkyl-imidamid Derivate |
| MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EP2235199A1 (en) | 2007-12-17 | 2010-10-06 | Lux Innovate Limited | Compositions and methods for maintenance of fluid conducting and containment systems |
| AR075153A1 (es) * | 2009-01-30 | 2011-03-16 | Glaxosmithkline Llc | Compuesto hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil)-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2- tiofenocarboxamida en forma cristalina, composicion farmaceitica que lo comprende, procedimiento para prepararla, su uso para preparar un medicamento util para tratar o disminuir la |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| PT3738434T (pt) | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SI3102208T1 (sl) | 2014-02-07 | 2021-07-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
| MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
| WO2017123766A1 (en) * | 2016-01-12 | 2017-07-20 | Sperovie Biosciences, Inc. | Compounds and compositions for the treatment of disease |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| RU2746012C2 (ru) * | 2019-05-13 | 2021-04-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956998A (en) | 1960-10-18 | Adenine derivatives and process | ||
| US2844577A (en) | 1958-07-22 | Certificate of correction | ||
| US3215696A (en) | 1965-11-02 | Substituted adenines -and preparation thereof | ||
| US2903455A (en) | 1959-09-08 | Jdnviiiiaisnvhi jo | ||
| US2697709A (en) | 1951-06-14 | 1954-12-21 | Burroughs Wellcome Co | Mercapto heterocycles and method of making |
| US2691654A (en) | 1952-06-11 | 1954-10-12 | Buroughs Wellcome & Co U S A I | Amino heterocycles and method of making |
| US2966488A (en) * | 1956-07-30 | 1960-12-27 | Shive William | Substituted alkylaminopurines |
| US2957875A (en) | 1957-11-18 | 1960-10-25 | Upjohn Co | Derivatives of purine |
| US3079378A (en) | 1960-02-01 | 1963-02-26 | Upjohn Co | Acylated psicofuranosyladenines |
| NL262940A (pt) * | 1960-03-31 | |||
| US3135753A (en) | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
| FR1548252A (pt) | 1961-10-13 | 1968-12-06 | ||
| IL24679A (en) * | 1965-11-24 | 1971-10-20 | Yissum Res Dev Co | Derivatives of 3-methyl purine and methods of preparing the same |
| US3669979A (en) | 1967-12-14 | 1972-06-13 | Gaf Corp | Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst |
| US3952001A (en) | 1970-07-01 | 1976-04-20 | The Boots Company Limited | 1-Carbamoyl-1,2,4-triazoles |
| JPS5121529A (ja) | 1974-08-16 | 1976-02-20 | Hitachi Ltd | Pirorinsandometsukizeiseihimakuboshiho |
| USRE31429E (en) | 1977-02-14 | 1983-10-25 | Merck & Co., Inc. | Process for preparation of 9-(dihalobenzyl)adenines |
| GB2041359B (en) * | 1979-01-10 | 1982-12-15 | Ici Ltd | Purine derivatives and their use in the defoliation of cotton plants |
| US4241063A (en) | 1979-08-06 | 1980-12-23 | Bristol-Myers Company | Purine derivatives and their use as bronchodilators |
| US4407802A (en) | 1981-09-28 | 1983-10-04 | Merck & Co., Inc. | 6-Amidino-9-substituted benzyl purines |
| US4361699A (en) | 1981-09-28 | 1982-11-30 | Merck & Co., Inc. | Novel process for the preparation of N6 -alkyl-arprinocid |
| GB2120065B (en) | 1982-04-27 | 1986-01-02 | Michael Frederick Huber | Heating plants |
| US4492592A (en) | 1983-06-06 | 1985-01-08 | Shell Oil Company | Combined desiccation of substantially supercritical CO2 |
| JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| US4883801A (en) | 1984-09-07 | 1989-11-28 | The General Hospital Corporation | Xanthine derivative pest control agents |
| GB8510758D0 (en) | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| WO1987006576A1 (en) | 1986-04-29 | 1987-11-05 | Pfizer Inc. | Calcium independent camp phosphodiesterase inhibitor antidepressant |
| GB8618931D0 (en) | 1986-08-02 | 1986-09-10 | Euro Celtique Sa | 6-thioxanthines |
| US5057517A (en) | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
| US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
| EP0363320A3 (de) | 1988-10-06 | 1991-11-21 | Ciba-Geigy Ag | Substituierte 9H-Purine |
| US4971972A (en) | 1989-03-23 | 1990-11-20 | Schering Corporation | Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion |
| US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| DE69033614T2 (de) | 1989-10-20 | 2001-04-19 | Kyowa Hakko Kogyo Kk | Kondensierte Purinderivate |
| US5117830A (en) | 1990-11-08 | 1992-06-02 | Whitby Research, Inc. | Method of determining viability of tissue |
| US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| DE69322254T2 (de) | 1992-01-13 | 1999-04-29 | Smithkline Beecham Corp | Pyridyl-substituierte imidazole |
| DE69309030T2 (de) | 1992-06-15 | 1997-09-25 | Celltech Therapeutics Ltd | Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren |
| MX9304571A (es) | 1992-07-28 | 1994-05-31 | Rhone Poulenc Rorer Ltd | Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador. |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| ATE234270T1 (de) | 1992-12-02 | 2003-03-15 | Pfizer | Cathecoldiether als selektive pde iv hemmungsmittel |
| GB9226830D0 (en) | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| TW263495B (pt) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| DE4309969A1 (de) | 1993-03-26 | 1994-09-29 | Bayer Ag | Substituierte heteroanellierte Imidazole |
| GB9312853D0 (en) * | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| FI951367A (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
-
1998
- 1998-12-10 BR BR9815170-3A patent/BR9815170A/pt not_active Application Discontinuation
- 1998-12-10 EP EP98962064A patent/EP1044201A4/en not_active Withdrawn
- 1998-12-10 WO PCT/US1998/026340 patent/WO1999031105A1/en not_active Application Discontinuation
- 1998-12-10 WO PCT/US1998/026338 patent/WO1999031103A1/en active Application Filing
- 1998-12-10 DE DE19882893T patent/DE19882893T1/de not_active Withdrawn
- 1998-12-10 US US09/209,658 patent/US6037470A/en not_active Expired - Lifetime
- 1998-12-10 WO PCT/US1998/026339 patent/WO1999031104A1/en active Application Filing
- 1998-12-10 DE DE19882892T patent/DE19882892T1/de not_active Withdrawn
- 1998-12-10 AU AU17230/99A patent/AU1723099A/en not_active Abandoned
- 1998-12-10 CA CA002313004A patent/CA2313004A1/en not_active Abandoned
- 1998-12-10 GB GB0013780A patent/GB2346878B/en not_active Expired - Fee Related
- 1998-12-10 JP JP2000539026A patent/JP2002508377A/ja active Pending
- 1998-12-10 AU AU17228/99A patent/AU1722899A/en not_active Abandoned
- 1998-12-10 HU HU0301166A patent/HUP0301166A2/hu unknown
- 1998-12-10 JP JP2000539028A patent/JP2002508379A/ja active Pending
- 1998-12-10 CN CN98812098A patent/CN1294590A/zh active Pending
- 1998-12-10 GB GB0013781A patent/GB2346879B/en not_active Expired - Fee Related
- 1998-12-10 JP JP2000539027A patent/JP2002508378A/ja active Pending
- 1998-12-10 AU AU17229/99A patent/AU1722999A/en not_active Abandoned
- 1998-12-10 US US09/209,664 patent/US6057445A/en not_active Expired - Fee Related
- 1998-12-10 KR KR1020007005963A patent/KR100349385B1/ko not_active IP Right Cessation
- 1998-12-10 US US09/209,922 patent/US6040447A/en not_active Expired - Lifetime
- 1998-12-11 CA CA002313150A patent/CA2313150A1/en not_active Abandoned
- 1998-12-11 WO PCT/US1998/026293 patent/WO1999031102A1/en active IP Right Grant
- 1998-12-11 JP JP2000539025A patent/JP3504234B2/ja not_active Expired - Fee Related
- 1998-12-11 CN CN98813362A patent/CN1284077A/zh active Pending
- 1998-12-11 AT AT98963053T patent/ATE244243T1/de not_active IP Right Cessation
- 1998-12-11 CA CA002314335A patent/CA2314335A1/en not_active Abandoned
- 1998-12-11 EP EP98963114A patent/EP1045850A4/en not_active Withdrawn
- 1998-12-11 WO PCT/US1998/026444 patent/WO1999029694A1/en not_active Application Discontinuation
- 1998-12-11 BR BR9815171-1A patent/BR9815171A/pt not_active Application Discontinuation
- 1998-12-11 US US09/210,556 patent/US6228859B1/en not_active Expired - Fee Related
- 1998-12-11 AU AU18159/99A patent/AU747366B2/en not_active Ceased
- 1998-12-11 ES ES98963053T patent/ES2202924T3/es not_active Expired - Lifetime
- 1998-12-11 AU AU18208/99A patent/AU1820899A/en not_active Abandoned
- 1998-12-11 US US09/210,557 patent/US6211367B1/en not_active Expired - Lifetime
- 1998-12-11 JP JP2000524287A patent/JP2001525412A/ja active Pending
- 1998-12-11 EP EP98963053A patent/EP1045849B1/en not_active Expired - Lifetime
- 1998-12-11 TR TR2000/01706T patent/TR200001706T2/xx unknown
- 1998-12-11 HU HU0100305A patent/HUP0100305A2/hu unknown
- 1998-12-11 PT PT98963053T patent/PT1045849E/pt unknown
- 1998-12-11 PL PL98341108A patent/PL341108A1/xx unknown
- 1998-12-11 DK DK98963053T patent/DK1045849T3/da active
- 1998-12-11 KR KR1020007006407A patent/KR20010033049A/ko not_active Application Discontinuation
- 1998-12-11 KR KR1020007006328A patent/KR20010032979A/ko not_active Application Discontinuation
- 1998-12-11 HU HU0100417A patent/HUP0100417A3/hu unknown
- 1998-12-11 DE DE69816127T patent/DE69816127T2/de not_active Expired - Fee Related
- 1998-12-11 CN CN98812064A patent/CN1281458A/zh active Pending
- 1998-12-11 BR BR9815169-0A patent/BR9815169A/pt not_active Application Discontinuation
-
2000
- 2000-06-09 NO NO20002998A patent/NO20002998L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9815170A (pt) | "método de obter composto aplicável no tratamento de asma em mamìferos" | |
| NO20000325L (no) | Absorbentsammensetning for rensing av gasser som inneholder sure komponenter | |
| DE60015606D1 (de) | Zusammensetzungen, enthaltend aminische antioxidantien auf basis von n-(4-anilinophenyl)amiden | |
| NO20012411L (no) | Pyrrolidin-derivater-CCR-3-reseptorantagonister | |
| KR920008122A (ko) | 히드록시 아릴트리아진 및 테트라알킬 피페리딘을 함유하는 상승적 안정제 조성물 및 이로써 중합체를 안정화하는 방법 | |
| BR0111230A (pt) | Composto, e, uso e processo para a preparação do mesmo | |
| FR2828487B1 (fr) | Nouveaux composes derives d'acides gras, preparation et utilisations | |
| ES2127919T3 (es) | 4-amino-piridinas, procedimiento para su preparacion, asi como medicamentos que contienen estos compuestos. | |
| BRPI0511814A (pt) | método de inibir manchamento quìmico de uma superfìcie dental, e, composição para cuidado oral | |
| DE69735992D1 (de) | Meso-substituierte tripyrrane derivate, zusammensetzungen und verwendungsmöglichkeiten sowie verfahren zu deren herstellung | |
| MXPA02008228A (es) | Metodo para la preparacion de citalopram. | |
| TW200500430A (en) | Crosslinking composition | |
| BR9713322A (pt) | Composição e método para tratamento de plantas com substâncias quìmicas exógenas | |
| TW200617048A (en) | Stabilized crosslinking composition | |
| EA199900648A1 (ru) | Замещенные производные (1,3-бис(циклогексилметил)-1,2,3,6-тетрагидро-2,6-диоксо-9н-пурин-8-ил) фенила, их получение и их применение при лечении воспалительных состояний и иммунных расстройств | |
| BR0311469A (pt) | Composto de monÈmero que compreende diversos grupos catiÈnicos e polìmeros que compreendem unidades obtidas a partir deste | |
| PT83234B (pt) | Processo para a preparacao de derivados de indolina e de composicoes farmaceuticas que os contem | |
| ATE93863T1 (de) | Enzym-hemmende aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung. | |
| ATE314352T1 (de) | Anilide als acat-hemmer | |
| DE69907656D1 (de) | Polyethoxylierte retinamid-derivate und verfahren zu ihrer herstellung | |
| ATE259847T1 (de) | Aziridinosilikone und deren verwendung | |
| BR8601792A (pt) | Composicao de esmalte de unha e processo para a preparacao da mesma | |
| ATE55109T1 (de) | Chemisches verfahren zur herstellung von abkoemmlingen von oxamid. | |
| FR2806726B1 (fr) | Procede de preparation de la (2s,3r,4s)-4-hydroxyisoleucine et de ses analogues | |
| BR0004764A (pt) | Compostos inibidores da reanimação de ciano-indol serotonina, um processo para sua preparação e composições farmacêuticas que os contêm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |